1. Pink Sheet
  2. >>Market Access
  3. >>Pricing Debate

HHS Secretary Azar Likely To Advance Medicare Drug Pricing Policies

 
• By Cathy Kelly

Alex Azar's nomination clears Senate with support from five Democrats and one Independent – but not Rand Paul, R-Ky.

Alex Azar, Trump’s HHS secretary nominee, who spoke at the Senate HELP committee 11/29/17
Alex Azar testifies at his confirmation hearing before the Senate HELP Committee on Nov. 29, 2017.

Now that his nomination to be HHS secretary has cleared the full Senate, Alex Azar is likely to focus on advancing the government's development of policies to reduce drug prices in Medicare Part D and Part B.

Azar's nomination was approved by the Senate in a 55-43 vote, with support from five Democrats and one Independent. (See...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Pricing Debate

Pink Sheet Podcast: The US and Ex-US Impact Of Most-Favored Nation Drug Pricing

 
• By Derrick Gingery, Francesca Bruce, Cathy Kelly, and Nielsen Hobbs

Pink Sheet reporter and editors discuss the potential impact of the Most-Favored Nation drug pricing proposal on Europe, the United States, as well as the pharmaceutical industry.

Crisis Or Opportunity? US MFN Policy Could Test Japan’s Appetite For Reforms

 
• By Lisa Takagi

While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.

‘Brainless’ US MFN Policy Could Drive Pharma Investment To Europe

 
• By Francesca Bruce

European health systems already pay far too much for new medicines and payers will not accept higher prices to compensate for lower US prices, according to Anja Schiel, from NOMA, the Norwegian health technology assessment body.

Payment Cap Not Always Solution For Unaffordable Drugs, Maryland PDAB Director Says

 
• By Cathy Kelly

The state's Prescription Drug Affordability Board, the oldest of a growing list of the boards, chose six drugs for affordability reviews and has the authority to set a ceiling on the amount state and local government payers would reimburse for them.

More from Market Access